Enhancement patterns and parameters of breast cancers at contrast-enhanced US: Correlation with prognostic factors

Radiology

Volumn 262, Issue 2, 2012, Pages 450-459

  Wan, Cai Feng ^a   Du, Jing ^a   Fang, Hua ^a   Li, Feng Hua ^a   Zhu, Jian Shan ^a   Liu, Qiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SONOVUE;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPH NODE; MAJOR CLINICAL STUDY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE ENHANCEMENT; MIDDLE AGED; PHOSPHOLIPIDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; SULFUR HEXAFLUORIDE; ULTRASONOGRAPHY, MAMMARY;

EID: 84863135234     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11110789     Document Type: Article

References (32)

1. Kim EA, Yoon KH, Lee YH, Kim HW, Juhng SK, Won JJ. Focal hepatic lesions: contrastenhancement patterns at pulse-inversion harmonic US using a microbubble contrast agent. Korean J Radiol 2003;4(4):224-233. (Pubitemid 38569463)
2. Yamaguchi A, Hayashi Y, Kojima Y, Miyagawa H, Ito M, Kohri K. Testicular torsion: usefulness of contrast-enhanced power Doppler sonography. Int J Urol 2005;12(9):849-851. (Pubitemid 41726985)
3. Tani T, Tanabe K, Tani M, et al. Quantitative assessment of harmonic power Doppler myocardial perfusion imaging with intravenous Levovist in patients with myocardial infarction: comparison with myocardial viability evaluated by coronary flow reserve and coronary flow pattern of infarct-related artery. Cardiovasc Ultrasound 2005;3:22.
4. Zhao H, Xu R, Ouyang Q, Chen L, Dong B, Huihua Y. Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions. Eur J Radiol 2010;73(2):288-293.
5. Caproni N, Marchisio F, Pecchi A, et al. Contrast-enhanced ultrasound in the characterisation of breast masses: utility of quantitative analysis in comparison with MRI. Eur Radiol 2010;20(6):1384-1395.
6. Vallone P, D'Angelo R, Filice S, et al. Colordoppler using contrast medium in evaluating the response to neoadjuvant treatment in patients with locally advanced breast carcinoma. Anticancer Res 2005;25(1B): 595-599. (Pubitemid 40470070)
7. Lamuraglia M, Lassau N, Garbay JR, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences: a prospective phase II study. Eur J Radiol 2005;56(3):376-381. (Pubitemid 41659388)
8. Szabó BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Boné B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 2003;13(11): 2425-2435. (Pubitemid 37407473)
9. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999;31(3):209-223. (Pubitemid 29424143)
10. Yaghan R, Stanton PD, Robertson KW, Going JJ, Murray GD, McArdle CS. Oestrogen receptor status predicts local recurrence following breast conservation surgery for early breast cancer. Eur J Surg Oncol 1998;24(5):424-426. (Pubitemid 28479094)
11. Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63(3):439-443.
12. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182(3):311-322. (Pubitemid 30054364)
13. Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr Relat Cancer 1999;6(1):51-59. (Pubitemid 29197229)
14. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36(2):169-180.
15. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235(4787):442- 447. (Pubitemid 17009577)
16. Tuncbilek N, Unlu E, Karakas HM, Cakir B, Ozyilmaz F. Evaluation of tumor angiogenesis with contrast-enhanced dynamic magnetic resonance mammography. Breast J 2003;9(5):403-408. (Pubitemid 37158916)
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403-410.
18. Böcker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics [in German]. Verh Dtsch Ges Pathol 2002;86:116-119.
19. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005;18(1):26-35. (Pubitemid 40128091)
20. Koukourakis MI, Manolas C, Minopoulos G, Giatromanolaki A, Sivridis E. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast. Int J Surg Pathol 2003;11(1):29-34. (Pubitemid 36227986)
21. Beliën JA, van Diest PJ, Baak JP. Relationships between vascularization and proliferation in invasive breast cancer. J Pathol 1999;189(3):309-318.
22. Fridman V, Humblet C, Bonjean K, Boniver J. Assessment of tumor angiogenesis in invasive breast carcinomas: absence of correlation with prognosis and pathological factors. Virchows Arch 2000;437(6):611-617. (Pubitemid 32003091)
23. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84(24):1875-1887. (Pubitemid 23004615)
24. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18(4):467-477. (Pubitemid 37187600)
25. Kuhl CK, Bieling H, Gieseke J, et al. Breast neoplasms: T2*susceptibility-contrast, firstpass perfusion MR imaging. Radiology 1997;202(1):87-95. (Pubitemid 27024112)
26. Metz S, Daldrup-Unk HE, Richter T, et al. Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent Gadophrin-3. Acad Radiol 2003;10(5):484-490. (Pubitemid 36534889)
27. Colpaert C, Vermeulen P, van Beest P, et al. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001;39(4):416-425. (Pubitemid 32990095)
28. Bos R, van Diest PJ, van der Groep P, Shvarts A, Greijer AE, van der Wall E. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 2004;6(4): R450-R459.
29. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200(3):639-649. (Pubitemid 26282258)
30. Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006;239(2):351-360.
31. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26(1):86-91.
32. Lichtenbeld HC, Barendsz-Janson AF, van Essen H, Struijker Boudier H, Griffioen AW, Hillen HF. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model. Int J Cancer 1998;77(3):455-459. (Pubitemid 28299884)